Cedric Francois, Apellis CEO

FDA ap­proves Apel­lis' reti­nal dis­ease drug as com­peti­tor ex­pects Au­gust de­ci­sion

The FDA ap­proved Apel­lis Phar­ma­ceu­ti­cals’ drug for ge­o­graph­ic at­ro­phy sec­ondary to age-re­lat­ed mac­u­lar de­gen­er­a­tion af­ter push­ing back the green light de­ci­sion by three months to go through more da­ta.

The biotech will mar­ket the drug as Syfovre. Known in­ves­ti­ga­tion­al­ly as pegc­eta­coplan in­jec­tion, Apel­lis al­ready mar­kets a ver­sion of the drug as Em­paveli for the rare dis­ease parox­ys­mal noc­tur­nal he­mo­glo­bin­uria.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.